CoChat

AKT1 and MYC Induce Distinctive Metabolic Fingerprints in Human Prostate Cancer

Open access
Priolo, Carmen, Pyne, Saumyadipta, Rose, Joshua, Regan, Erzsébet Ravasz, Zadra, Giorgia, Photopoulos, Cornelia, Cacciatore, Stefano, Schultz, Denise, Scaglia, Natalia, McDunn, Jonathan, De Marzo, Angelo M., Loda, Massimo · 2014 · Cancer Research
Cited by 134

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Cancer cells may overcome growth factor dependence by deregulating oncogenic and/or tumor-suppressor pathways that affect their metabolism, or by activating metabolic pathways de novo with targeted mutations in critical metabolic enzymes. It is unknown whether human prostate tumors develop a similar metabolic response to different oncogenic drivers or a particular oncogenic event results in its own metabolic reprogramming. Akt and Myc are arguably the most prevalent driving oncogenes in prostate cancer. Mass spectrometry–based metabolite profiling was performed on immortalized human prostate epithelial cells transformed by AKT1 or MYC, transgenic mice driven by the same oncogenes under the control of a prostate-specific promoter, and human prostate specimens characterized for the expression and activation of these oncoproteins. Integrative analysis of these metabolomic datasets revealed that AKT1 activation was associated with accumulation of aerobic glycolysis metabolites, whereas MYC overexpression was associated with dysregulated lipid metabolism. Selected metabolites that differentially accumulated in the MYC-high versus AKT1-high tumors, or in normal versus tumor prostate tissue by untargeted metabolomics, were validated using absolute quantitation assays. Importantly, the AKT1/MYC status was independent of Gleason grade and pathologic staging. Our findings show how prostate tumors undergo a metabolic reprogramming that reflects their molecular phenotypes, with implications for the development of metabolic diagnostics and targeted therapeutics. Cancer Res; 74(24); 7198–204. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-14-1490

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 134

Metadata

Authors
Priolo, C., Pyne, S., Rose, J., Regan, E. R., Zadra, G., Photopoulos, C., Cacciatore, S., Schultz, D., Scaglia, N., McDunn, J., De Marzo, A. M., & Loda, M.
Venue
Cancer Research
Published
2014-12-14
Volume
74
Issue
24
Pages
7198-7204
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2077058200
Cited by
134
References
6
FWCI
2.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AKT1 and MYC Induce Distinctive Metabolic Fingerprints in Human Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-1490
The paper
Priolo, C., Pyne, S., Rose, J., Regan, E. R., Zadra, G., Photopoulos, C., Cacciatore, S., Schultz, D., Scaglia, N., McDunn, J., De Marzo, A. M., & Loda, M. (2014). AKT1 and MYC Induce Distinctive Metabolic Fingerprints in Human Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-1490

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.